object
explor
transcriptom
differ
patient
hypertroph
cardiomyopathi
hcm
control
patient
method
rna
extract
cardiac
tissu
flash
frozen
therapeut
surgic
septal
myectomi
patient
hcm
healthi
donor
heart
express
profil
gene
perform
use
illumina
human
express
beadchip
hcm
patient
genotyp
pathogen
variant
caus
hcm
technic
valid
perform
use
quantit
realtim
pcr
qrtpcr
western
blot
overal
transcriptom
gene
express
differenti
hcm
control
tissu
analysi
genotyp
reveal
gene
express
chang
similar
among
genotyp
subgroup
hcm
transcriptom
exhibit
differenti
express
genotyp
subgroup
qrtpcr
confirm
differenti
express
test
transcript
notabl
context
transcript
neg
regul
angiotensin
system
singl
upregul
gene
hcm
foldchang
confirm
qrtpcr
triplic
foldchang
western
blot
confirm
overexpress
protein
foldchang
conclus
transcriptom
express
differenti
hcm
control
tissu
importantli
upregul
gene
hcm
indic
perhap
heart
compensatori
effort
mount
antihypertroph
antifibrot
respons
howev
given
use
viral
entri
increas
protein
may
hypertroph
cardiomyopathi
hcm
affect
approxim
individu
among
lead
caus
identifi
sudden
cardiac
death
scd
young
hcm
often
genet
diseas
typic
autosom
domin
inherit
defin
clinic
cardiac
hypertrophi
without
physiolog
explan
hundr
pathogen
variant
mani
hcmsuscept
gene
identifi
encod
compon
sarcomer
howev
genet
test
neg
approxim
unrel
patient
hcm
diagnos
clinic
studi
addit
transcript
chang
caus
result
hcm
without
pathogen
variant
remain
larg
unknown
prior
studi
analyz
data
small
number
patient
better
identifi
common
transcript
chang
repres
fundament
heretofor
unrecogn
pathogen
respons
human
hcm
perform
transcriptom
analysi
human
hcm
tissu
design
casecontrol
studi
identifi
mrna
differenti
express
hcmaffect
myocardium
versu
control
myocardium
patient
sign
inform
consent
protocol
approv
mayo
clinic
institut
review
board
human
research
ethic
committe
univers
sydney
studi
start
januari
final
analysi
complet
april
patient
undergo
therapeut
surgic
septal
myectomi
symptomat
relief
obstruct
hcm
januari
decemb
elig
inclus
studi
diagnosi
hcm
made
experienc
cardiologist
mayo
clinic
hcm
clinic
base
physic
exam
ecg
echocardiographiccardiac
mri
find
diagnosi
corrobor
histolog
examin
patient
surgic
septal
myectomi
specimen
repres
portion
myectomi
specimen
flash
frozen
time
excis
subsequ
store
c
data
patient
age
sex
age
diagnosi
new
york
heart
associ
nyha
classif
blood
pressur
heart
rate
famili
histori
hcm
famili
histori
scd
extract
patient
electron
medic
record
echocardiograph
paramet
extract
patient
preoper
echocardiographi
studi
degre
endocardi
interstiti
fibrosi
assess
semiquantit
time
resect
cardiovascular
pathologist
jjm
cohort
control
tissu
procur
univers
sydney
consist
donor
heart
suitabl
transplant
recipi
normal
phenotyp
confirm
cardiac
examin
ecg
echocardiogram
obtain
within
hour
prior
explant
dna
extract
hcm
myectomi
control
donor
heart
tissu
use
qiagen
puregen
dna
purif
kit
qiagen
inc
accord
manufactur
protocol
briefli
cell
lyse
deterg
rna
remov
use
rnase
enzym
protein
remov
salt
precipit
dna
recov
alcohol
precipit
damag
variant
gene
implic
sarcomer
hcm
gene
known
mimic
hcm
gla
studi
use
filterbas
hybrid
captur
describ
previous
tissu
section
deparaffin
xylen
dip
decreas
concentr
ethyl
alcohol
rehydr
distil
water
antigen
retriev
perform
place
slide
preheat
citrat
retriev
solut
steamer
minut
xylen
perform
prior
perman
coverslip
slide
grade
cardiac
pathologist
jjm
grade
intens
stain
dotlik
sarcoplasm
stain
sarcoplasm
stain
distribut
score
cell
cell
stain
specimen
alloc
randomli
array
use
random
block
method
order
avoid
confound
biolog
experiment
effect
illumina
beadstudio
version
gene
express
modul
use
process
raw
data
without
background
correct
normal
gene
level
express
data
export
analyz
r
http
wwwrprojectorg
briefli
unnorm
raw
data
first
transform
evalu
potenti
outlier
sampl
bead
chip
effect
graphic
dimens
reduct
approach
densiti
plot
plot
princip
compon
analysi
outlier
sampl
exclud
analys
remain
good
sampl
normal
togeth
use
fastlo
modelbas
intensitydepend
normal
method
produc
result
essenti
cyclic
loess
fraction
time
gene
level
express
compar
hcm
normal
tissu
genotyp
subgroup
overal
follow
pairwis
contrast
via
anova
linear
model
togeth
fals
discoveri
rate
fdr
gene
fdr
qvalu
consid
statist
signific
hcm
normal
tissu
comparison
pairwis
comparison
differ
genotyp
subgroup
hcm
pvalu
consid
statist
signific
less
stringent
cutoff
use
effort
elucid
differ
two
similar
diseas
condit
acknowledg
fact
chanc
fals
posit
result
higher
cutoff
biolog
signific
set
absolut
fold
chang
genotyp
subset
hcm
qrtpcr
data
analyz
calcul
averag
valu
transcript
interest
minu
gapdh
control
triplic
replic
sampl
onetail
ttest
use
foldchang
calcul
method
take
overal
averag
case
divid
overal
averag
control
hcm
particip
provid
written
inform
consent
particip
mayo
notabl
angiotensin
iangiotensin
ii
convert
enzym
subtyp
import
counterregul
reninangiotensinaldosteron
system
raa
involv
hypertrophi
fibrosi
vasoconstrict
upregul
gene
hcm
tissu
increas
vs
control
confirm
qrtpcr
figur
western
blot
analys
indic
increas
protein
express
compar
control
p
figur
addit
immunohistochemistri
cardiomyocyt
stain
cardiac
myectomi
tissu
hcm
patient
show
significantli
increas
stain
intens
distribut
p
protein
compar
control
sampl
figur
interestingli
locat
xchromosom
therefor
sexdiffer
could
expect
thu
perform
sexcorrect
analysi
express
data
observ
still
subgroup
analys
perform
compar
three
largest
genotyp
subset
genotyp
negativehcm
pairwis
comparison
genotyp
negativehcm
genotyp
negativehcm
perform
gene
express
chang
met
fals
discoveri
rate
qvalu
suggest
high
probabl
fals
posit
find
howev
given
diseas
state
comparison
previous
document
phenotyp
indistinguish
clinic
gross
anatom
microscop
level
hypothes
gene
express
chang
due
genotyp
subgroup
might
subtl
therefor
accept
higher
fals
posit
rate
order
reveal
potenti
import
differ
gene
express
adjust
meet
pvalu
gene
express
chang
subgroup
comparison
total
approxim
gene
test
differenti
express
gene
low
absolut
fold
chang
high
fals
discoveri
rate
qvalu
overal
comparison
gene
express
among
genotyp
subgroup
hcm
reveal
gene
express
chang
share
sinc
addit
differ
genotyp
subgroup
subtl
summar
supplement
data
analysi
hcm
myectomi
tissu
control
tissu
identifi
differenti
express
gene
gene
analyz
gene
particip
molecular
function
process
defin
gene
ontolog
consortium
remark
differenti
express
gene
previous
identifi
hypertroph
pathway
whether
reflect
rel
small
size
studi
group
variabl
age
treatment
background
genotyp
factor
unknown
previou
genotypephenotyp
studi
identifi
genespecif
profil
nevertheless
suggest
newli
identifi
differenti
express
gene
warrant
investig
given
current
devast
pandem
million
confirm
case
claim
live
worldwid
less
month
noteworthi
upregul
gene
hcm
sampl
qvalu
protein
also
increas
western
blot
analys
p
encod
angiotensin
convert
enzym
subtyp
import
compensatori
role
modul
excess
activ
raa
occur
hypertens
htn
congest
heart
failur
chf
atherosclerosi
solubl
form
act
carboxypeptidas
cleav
prohypertroph
polypeptid
angiotensin
angiotensin
ii
angiotensin
angiotensin
respect
therebi
produc
counterregul
vasodil
potenti
antihypertrophicantifibrot
polypeptid
figur
accordingli
specul
upregul
transcript
protein
level
might
compensatori
counterregulatori
signal
respons
pathorespons
patient
obstruct
hcm
echo
recent
paper
liu
et
al
investig
studi
transcriptom
hcm
mous
model
found
profibrot
pathway
initi
increas
main
driver
hcm
pathogenesi
mice
signal
howev
use
preliminari
microarray
data
deriv
patient
studi
made
publicli
avail
differenti
express
gene
observ
instead
increas
transcript
level
note
prompt
specul
overexpress
might
compensatori
respons
lastli
locat
xchromosom
upregul
significantli
femal
patient
hcm
fold
compar
male
p
one
gene
find
like
could
start
shed
light
form
basi
understand
underli
epigenet
contribut
significantli
differ
outcom
observ
women
hcm
beyond
potenti
relev
express
hcm
heart
diseas
pathogenesi
membranebound
state
play
import
role
function
receptor
requir
viral
entri
subsequ
viral
replic
sarscov
famili
virus
therebi
may
fact
contribut
increas
morbid
mortal
adult
patient
varieti
heart
diseas
current
endem
member
sarsfamili
coronavirus
bind
membranebound
via
viral
spike
protein
express
mani
tissu
includ
intestin
vascular
epithelium
kidney
heart
howev
express
cardiomyocyt
quit
low
fact
studi
cardiac
cell
sampl
donor
heart
show
highest
express
heart
tissu
pericyt
subpopul
rather
cardiomyocyt
nevertheless
widespread
express
may
contribut
multiorgan
dysfunct
seen
patient
mark
increas
protein
hcm
may
provid
mechan
explain
higher
rate
sever
outcom
patient
also
cardiovascular
comorbid
well
direct
cardiac
damag
caus
infect
incid
seem
highest
elderli
immunocompromis
larg
number
affect
patient
requir
hospit
suffer
signific
comorbid
includ
highli
preval
cardiovascular
diseas
htn
chf
larg
metaanalysi
patient
china
show
common
comorbid
htn
ci
diabet
mellitu
ci
cardiovascular
diseas
ci
percentag
much
higher
patient
requir
hospit
even
icu
admiss
two
separ
inpati
studi
preexist
htn
present
icu
nonsurviv
patient
concomit
cardiovascular
diseas
increas
icu
nonsurviv
patient
mount
evid
cardiotrop
infect
direct
cardiac
toxic
effect
ace
acei
inhibitor
angiotensin
receptor
blocker
arb
activ
investig
although
initi
report
suggest
potenti
wors
outcom
patient
ace
inhibitor
subsequ
review
articl
conclud
insuffici
evid
claim
prompt
major
cardiac
societi
advis
heart
diseas
patient
treat
medic
continu
hand
arb
could
attenu
impact
block
damag
effect
result
viralmedi
decreas
subsequ
increas
damag
angiotensin
ii
fact
experiment
studi
relat
viru
sarscov
show
downregul
exacerb
lung
injuri
treatment
arb
losartan
mitig
effect
furthermor
larg
studi
among
patient
htn
diagnos
show
unadjust
mortal
rate
significantli
lower
whose
htn
treat
aceiarb
vs
p
risk
remain
consist
lower
perform
propens
scorematch
analysi
adjust
imbalanc
variabl
age
gender
comorbid
inhospit
medic
adjust
hr
ci
p
light
find
clinic
trial
launch
test
effect
losartan
studi
elig
patient
figur
addit
clinic
grade
human
recombin
solubl
block
earli
stage
infect
significantli
prevent
viru
enter
cell
highlight
crucial
dual
role
health
diseas
figur
clinic
trial
test
patient
commenc
recent
europ
studi
hcm
patient
undergo
therapeut
surgic
septal
myectomi
repres
one
phenotyp
subset
hcm
howev
studi
design
inher
bia
procedur
provid
mean
ethic
obtain
heart
tissu
therefor
remain
determin
whether
elev
marker
state
diseas
alon
obstruct
hcm
whether
persist
follow
relief
lvoto
whether
elev
present
heart
patient
nonobstruct
hcm
cardiomyopathi
htn
form
acquir
heart
diseas
unknown
overcom
logist
ethic
issu
obtain
healthi
heart
tissu
use
common
sourc
healthi
heart
tissu
control
due
scarciti
reagent
need
control
tissu
procur
flashfrozen
preserv
rna
